BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
Public ClinicalTrials.gov record NCT05943106. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIIb Open-Label, Single-Arm, Multi-Center, US Study of Bacillus Calmette-Guerin (BCG) Administered in Combination With Durvalumab in Adult BCG-naïve, High-risk Non-Muscle- Invasive Bladder Cancer Participants (PATAPSCO)
Study identification
- NCT ID
- NCT05943106
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Interventions
- BCG Biological
- Durvalumab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 10, 2023
- Primary completion
- Jun 15, 2025
- Completion
- Mar 30, 2027
- Last update posted
- Mar 10, 2026
2023 – 2027
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | 85054 | — |
| Research Site | Little Rock | Arkansas | 72211 | — |
| Research Site | San Diego | California | 92123 | — |
| Research Site | Lakewood | Colorado | 80228 | — |
| Research Site | Hialeah | Florida | 33016 | — |
| Research Site | Jacksonville | Florida | 32209 | — |
| Research Site | Greenwood | Indiana | 46143 | — |
| Research Site | Wichita | Kansas | 67226 | — |
| Research Site | Baltimore | Maryland | 21203 | — |
| Research Site | Hanover | Maryland | 21076 | — |
| Research Site | Royal Oak | Michigan | 48073 | — |
| Research Site | Troy | Michigan | 48084 | — |
| Research Site | Syracuse | New York | 13210 | — |
| Research Site | Cincinnati | Ohio | 45212 | — |
| Research Site | Bala-Cynwyd | Pennsylvania | 19004-1017 | — |
| Research Site | Myrtle Beach | South Carolina | 29572 | — |
| Research Site | Nashville | Tennessee | 37209 | — |
| Research Site | Austin | Texas | 78759 | — |
| Research Site | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05943106, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 10, 2026 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05943106 live on ClinicalTrials.gov.